Scaling Non-Viral Gene Delivery: Lonza’s LV PRO Breakthrough in T Cell Manufacturing

Published on Lonza Poster Presentation (CT-PO024)

Non-viral electroporation continues to gain ground as a safer, scalable alternative to viral methods for cell and gene therapy. In this technical poster, Lonza presents data on its upgraded 4D-Nucleofector® LV Unit PRO system, demonstrating efficient delivery of complex cargos—including CRISPR-Cas9 components and large plasmids—into up to 1 billion T cells per run. The results show high viability and transfection consistency across donors, setting a strong precedent for large-scale manufacturing of gene-modified cells.

Read the full poster on Lonza:

👉 Non-viral delivery of large cargos for large-scale T cell manufacturing (PDF)

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.